 |
 |
 |
 |
SYMBION HEALTH: ACCC Won't Interfere in Primary's AU$2.65BB Bid
The Australian Competition and Consumer Commission said it would not intervene in Primary Health Care Ltd.'s AU$2.65 billion bid for rival Symbion Health Ltd., Sonali Paul and Jonathan Standing report for Reuters.
The regulator, according to Helen Schuller of Egoli News, has already conducted an informal review of the bid and has considered the information provided during its market inquiries and other relevant information.
Egoli quotes the regulator as saying, "based on that information, the ACCC does not propose to intervene in the matter pursuant to section 50 of the Trade Practices Act 1974."
According to analysts interviewed by Reuters, the most likely outcome to the takeover battle would be for Primary to raise its offer by including shares, or for Primary and Healthscope to carve up Symbion.
The Troubled Company Reporter-Asia Pacific yesterday reported that Symbion blocked both rivals from talking to each other before January 26, a move that Healthscope doesn't like.
The Symbion board has repeatedly rejected Primary's offer saying it is too low.
About Symbion Health
Symbion Health Limited, headquartered in Melbourne, is a diversified Australian domestic health care business. Most of its earnings are derived from the provision of pathology and diagnostic imaging services. The company also manufactures and markets vitamin and mineral supplements (consumer nutriceuticals). In addition, it operates a wholesale medical products distribution network, focusing on the distribution of prescription drugs to pharmacies and hospitals.
* * *
On Jan. 30, 2007, Moody's Investors Service placed the Ba1issuer rating of Symbion Health Limited on review for possible downgrade after the company's announcement that it has received an ownership proposal from Primary Health Care Limited (unrated).
|
 |
|
 |
|